Ireland-based drug developer Elan has spun out its research and development unit but will retain a 14% to 18% stake.
Elan will fund the drug discovery unit, Neotope Biosciences, and will provide $130m, which is about two years’ worth of funding for its research, according to news provider Fierce Biotech.
Dale Schenk is chief executive of Neotope.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
